Summary
In the seven major markets (7MM: US, EU4, UK, Japan), diagnosed cases of CVI reached ~17 million in 2024. Prevalence is projected to grow at a 1.4% CAGR, reaching ~20 million by 2034, driven by aging populations, obesity, sedentary lifestyles, and improved diagnostics.
Endovenous laser ablation (EVLA) and radiofrequency ablation (RFA) are now first-line interventional options, offering high success rates, minimal invasiveness, and rapid recovery.
Device-based therapies include enVVeno’s VenoValve, a bioprosthetic venous valve with FDA Breakthrough Device Designation, and the less invasive EnVVe transcatheter system.
Theraclion’s SONOVEIN use...
